Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A retinopathy caused by gain of function, heterozygous variants in the RDH12 gene, and associated with late onset retinopathy with a mild phenotype, characterized by nyctalopia and visual field loss, but relatively preserved central vision.
No clinical trials have been registered for RDH12-related dominant retinopathy.
1 publication has been identified in PubMed for RDH12-related dominant retinopathy. Research spans Basic Science / Preclinical (100%).
Méjécase C (2025). [PMID: 40365019](https://pubmed.ncbi.nlm.nih.gov/40365019/). *Front Cell Dev Biol*. [Basic Science / Preclinical]
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 8:42 AM UTC
Common questions about RDH12-related dominant retinopathy